According to a recent LinkedIn post from Neuromod Devices Ltd, the company is present at the 2026 Joint Defense Veterans Audiology Conference, with representatives at Booth #11 highlighting its Lenire tinnitus therapy for U.S. veterans. The post notes that Lenire is available as an option for approximately 3.2 million veterans living with tinnitus through the U.S. Department of Veterans Affairs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights ongoing commercial engagement with the Veterans Affairs channel, suggesting an effort to deepen adoption of its FDA-approved neuromodulation device in the U.S. veterans’ healthcare system. For investors, increased visibility at a specialized audiology conference may indicate a targeted strategy to expand utilization in a defined, reimbursed population, which could support more predictable revenue and strengthen Neuromod’s position in the tinnitus care and hearing health market.